Open Access

Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma

  • Authors:
    • Koichi Inami
    • Kazunori Kajino
    • Masaaki Abe
    • Yoshiaki Hagiwara
    • Masahiro Maeda
    • Masafumi Suyama
    • Sumio Watanabe
    • Okio Hino
  • View Affiliations

  • Published online on: December 1, 2008     https://doi.org/10.3892/or_00000155
  • Pages: 1375-1380
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

ERC/mesothelin gene (MSLN) encodes a precursor protein, which is cleaved by proteases to generate N-ERC/mesothelin and C-ERC/mesothelin. N-ERC/mesothelin is a soluble protein, also known as megakaryocyte-potentiating factor, which is released into extracellular space. N-ERC/mesothelin is known to be a serum marker of mesothelioma. We have previously developed an enzyme-linked immunosorbent assay system for N-ERC/mesothelin, which can detect mesothelioma. C-ERC/mesothelin is expressed in normal mesothelial cell, pancreatic cancers, ovarian cancers, mesotheliomas and some other cancers. Pancreatic ductal carcinoma remains a fatal disease because its diagnosis often occurs very late. In this study, we examined ERC/mesothelin expression in human pancreatic cancer cell lines (MIA-PaCa2, PK-1, KP-3, TCC-PAN2, PK-59 and PK-45H) by reverse transcription-polymerase chain reaction and immunoblotting and N-ERC/mesothelin concentration in the supernatant of cultured cancer cells by the ELISA system. We also investigated C-ERC/mesothlein expression in human pancreatic ductal carcinoma tissues by immunostaining using 5B2 anti-mesothelin monoclonal antibody and N-ERC/mesothelin concentration in sera obtained from patients with pancreatic ductal carcinoma via ELISA. In vitro, N-ERC/mesothelin concentration in cell culture medium nearly correlated with the expression level of C-ERC/mesothelin. Although C-ERC/mesothelin was frequently expressed in human pancreatic ductal carcinoma, serum N-ERC/mesothelin concentration of cancer patients was equivalent to healthy controls. N-ERC/mesothelin was not useful as a serum marker of pancreatic ductal carcinoma, but because of frequent expression, C-ERC/mesothelin might be useful as a target of molecular imaging and immunotherapy.

Related Articles

Journal Cover

December 2008
Volume 20 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Inami K, Kajino K, Abe M, Hagiwara Y, Maeda M, Suyama M, Watanabe S and Hino O: Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep 20: 1375-1380, 2008
APA
Inami, K., Kajino, K., Abe, M., Hagiwara, Y., Maeda, M., Suyama, M. ... Hino, O. (2008). Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncology Reports, 20, 1375-1380. https://doi.org/10.3892/or_00000155
MLA
Inami, K., Kajino, K., Abe, M., Hagiwara, Y., Maeda, M., Suyama, M., Watanabe, S., Hino, O."Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma". Oncology Reports 20.6 (2008): 1375-1380.
Chicago
Inami, K., Kajino, K., Abe, M., Hagiwara, Y., Maeda, M., Suyama, M., Watanabe, S., Hino, O."Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma". Oncology Reports 20, no. 6 (2008): 1375-1380. https://doi.org/10.3892/or_00000155